Circulating miRNA-29b and Sclerostin Levels Correlate with Coronary Artery Calcification and Cardiovascular Events in Maintenance Hemodialysis Patients

Figure 3

Serum levels of sclerostin and miRNA-29b were correlated with CVEs in MHD patients. (a) The Kaplan–Meier method with the log-rank test to estimate the cumulative risk of CVEs in MHD patients according to CACs. (b) The Kaplan–Meier method with the log-rank test to estimate the cumulative risk of CVEs in MHD patients according to serum levels of sclerostin (491.88 pg/mL as cutoff). (c) The Kaplan–Meier method with the log-rank test to estimate the cumulative risk of CVEs in MHD patients according to serum levels of miRNA-29b (Ct of 25.15 as cutoff).

(a)

(b)

(c)